Sulfation patterns in heparin and heparan sulfate: effects on the proliferation of bovine pulmonary artery smooth muscle cells

被引:30
作者
Garg, HG [1 ]
Yu, LY
Hales, CA
Toida, T
Islam, T
Linhardt, RJ
机构
[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Pulm Crit Care Unit, Boston, MA 02114 USA
[2] Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan
[3] Univ Iowa, Dept Chem, Iowa City, IA 52242 USA
[4] Rensselaer Polytech Inst, Dept Biol & Chem, Troy, NY 12180 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2003年 / 1639卷 / 03期
关键词
heparin; heparan sulfate; smooth muscle cell; proliferation; post-column derivatization HPLC; H-1; NMR;
D O I
10.1016/j.bbadis.2003.09.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heparin's (HP's) antiproliferative effect on smooth muscle cells is potentially important in defining new approaches to treat pulmonary hypertension. The commercially available HP and heparan sulfate (HS) are structurally heterogenous polymers. In order to examine which sulfonate groups are required for endogenous antiproliferative activity, we prepared the following six chemically modified porcine mucosal HP and HS, which fell into three groups. One group consisted of fully O-sulfonated-N-acetylated, the second group consisted of de-N-sulfonated and re-N-acetylated, and the third group consisted of 6-O-desulfonated HP and HS derivatives. These six preparations were assayed for their antiproliferative potency on bovine pulmonary artery smooth muscle cells. The results of this assay show that (a) over-O-sulfonation of both HP and HS increases antiproliferative activity, (b) substitution of hexosamine with N-acetyl diminishes antiproliferative activity in both HP and HS, and (c) 6-O-desulfonation of HP and HS diminishes antiproliferative potency. Surprisingly, the type of uronic acid residue present at a given level of sulfation is unimportant for antiproliferative potency. In conclusion, only the level of O- and N-sulfo group substitution correlates well with HP and HS antiproliferative activity. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 22 条
[1]   ENDOTHELIAL-CELL PROTEOGLYCANS - POSSIBLE MEDIATORS OF VASCULAR-RESPONSES TO INJURY [J].
BENITZ, WE ;
BERNFIELD, M .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1990, 2 (05) :407-408
[2]   STRUCTURAL DETERMINANTS OF THE CAPACITY OF HEPARIN TO INHIBIT THE PROLIFERATION OF VASCULAR SMOOTH-MUSCLE CELLS .2. EVIDENCE FOR A PENTASACCHARIDE SEQUENCE THAT CONTAINS A 3-O-SULFATE GROUP [J].
CASTELLOT, JJ ;
CHOAY, J ;
LORMEAU, JC ;
PETITOU, M ;
SACHE, E ;
KARNOVSKY, MJ .
JOURNAL OF CELL BIOLOGY, 1986, 102 (05) :1979-1984
[3]   STRUCTURAL DETERMINANTS OF THE CAPACITY OF HEPARIN TO INHIBIT THE PROLIFERATION OF VASCULAR SMOOTH-MUSCLE CELLS [J].
CASTELLOT, JJ ;
BEELER, DL ;
ROSENBERG, RD ;
KARNOVSKY, MJ .
JOURNAL OF CELLULAR PHYSIOLOGY, 1984, 120 (03) :315-320
[4]  
CASU B, 1989, ANN NY ACAD SCI, V556, P1
[5]   Differential effect of three commercial heparins on Na+/H+ exchange and growth of PASMC [J].
Dahlberg, CGW ;
Thompson, BT ;
Joseph, PM ;
Garg, HG ;
Spence, CR ;
Quinn, DA ;
Bonventre, JV ;
Hales, CA .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 1996, 270 (02) :L260-L265
[6]   INTEGRAL MEMBRANE HEPARAN-SULFATE PROTEOGLYCANS [J].
DAVID, G .
FASEB JOURNAL, 1993, 7 (11) :1023-1030
[7]   Effect of fully sulfated glycosaminoglycans on pulmonary artery smooth muscle cell proliferation [J].
Garg, HG ;
Joseph, PAM ;
Thompson, BT ;
Hales, CA ;
Toida, T ;
Imanari, T ;
Capila, I ;
Linhardt, RJ .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1999, 371 (02) :228-233
[8]   STRUCTURE OF COLLAGEN FIBRIL-ASSOCIATED, SMALL PROTEOGLYCANS OF MAMMALIAN ORIGIN [J].
GARG, HG ;
LYON, NB .
ADVANCES IN CARBOHYDRATE CHEMISTRY AND BIOCHEMISTRY, 1991, 49 :239-261
[9]   Antiproliferative role of 3-O-sulfate glucosamine in heparin on cultured pulmonary artery smooth muscle cells [J].
Garg, HG ;
Joseph, PAM ;
Yoshida, K ;
Thompson, BT ;
Hales, CA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 224 (02) :468-473
[10]  
GARG HG, 2002, PROTEOGLYCANS LUNG D, P377